A Phase III, Multicenter, Randomized, Placebo - Controlled, Double - Blind Study Of Atezolizumab (Anti − PD - L1 Antibody) As Adjuvant Therapy In
Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy
In 1999, CRI researchers including Neil Bander, M.D., Dirk Jäger, M.D., Elke Jäger, M.D., Alexander Knuth, M.D., and Lloyd J. Old, M.D., used SEREX technology to identify tumor - associated antigens in patients
with renal cell carcinoma.
Researchers studied food questionnaires for 335 people
with renal cell carcinoma, the most common form of kidney cancer, and 337 healthy controls.
The pathogenetic relationship between tumour and hypertension was investigated in 129 patients
with renal cell carcinoma, of whom 41 (31.8 %) were hypertensive.